BIOTECH: HL Buys, Sells; New Partnership Unveiled for Illumina
Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.
San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.
Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.
BIOTECH: Company focused on mitochondria health, raises $85M round
Boosting ambitious plans, Epirium recently secured an $85 million Series A round, amid greater investment in muscle therapies.
HEALTH: Excise Tax Was an ACA Financing Mechanism
A recently signed federal spending bill repealed a 2.3% excise tax on medical device makers that was scheduled to resume this month, a boon to San Diego’s medtech industry.